Preface |
|
xi | |
|
1 Definition, History, Nosology, and Classification |
|
|
1 | (8) |
|
Introduction and Definition |
|
|
1 | (1) |
|
|
2 | (1) |
|
Nosology and Classification Scheme |
|
|
3 | (2) |
|
Classification Level 1: Pism---Division Into Complex Pism and Simple Pism |
|
|
5 | (1) |
|
Classification Level 2: Specific Diagnosis Based on Etiology |
|
|
5 | (1) |
|
Ambiguities and Future Directions |
|
|
6 | (1) |
|
|
7 | (2) |
|
|
9 | (16) |
|
|
9 | (2) |
|
|
11 | (1) |
|
|
12 | (1) |
|
|
13 | (2) |
|
|
15 | (5) |
|
Implications for Understanding Etiopathogenesis and Anticipating the Future Burden of Pd |
|
|
20 | (5) |
|
|
25 | (18) |
|
|
25 | (1) |
|
|
26 | (1) |
|
Gross Pathology, Lewy Pathology, and α-Synucleinopathy |
|
|
27 | (3) |
|
Substantia Nigra Pars Compacta Pathologies |
|
|
30 | (2) |
|
Incidental Lewy Body Disease |
|
|
32 | (1) |
|
The Braak Et Al. Staging System |
|
|
33 | (4) |
|
Synucleinopathy Outside the Brain |
|
|
37 | (1) |
|
Non-Synucleinopathy Pathologies |
|
|
37 | (6) |
|
4 Pathophysiology I: Basal Ganglia Architecture and the Standard Model |
|
|
43 | (18) |
|
|
43 | (1) |
|
Basic Basal Ganglia Architecture |
|
|
44 | (6) |
|
The "Standard" Model of Basal Ganglia Pathophysiology |
|
|
50 | (4) |
|
Complexities of Basal Ganglia Architecture |
|
|
54 | (4) |
|
|
58 | (3) |
|
5 Pathophysiology II: Neurotransmitter Systemdysfunctions |
|
|
61 | (16) |
|
|
61 | (1) |
|
Nigrostriatal Dopamine Signaling Functions |
|
|
61 | (5) |
|
Habit Formation and Chunking |
|
|
66 | (1) |
|
Cholinergic Projection System Dysfunctions |
|
|
67 | (4) |
|
Serotoninergic System Dysfunctions |
|
|
71 | (1) |
|
Conclusion and Future Challenges |
|
|
72 | (5) |
|
6 Genetics of Parkinson Disease |
|
|
77 | (16) |
|
|
77 | (2) |
|
|
79 | (4) |
|
|
83 | (2) |
|
|
85 | (2) |
|
|
87 | (1) |
|
Implications of Pd Genetic Research |
|
|
88 | (5) |
|
|
93 | (32) |
|
|
93 | (4) |
|
|
97 | (2) |
|
The Prion-Like Hypothesis |
|
|
99 | (3) |
|
Mitochondrial Dysfunction |
|
|
102 | (2) |
|
|
104 | (4) |
|
Endolysosomal Dysfunction |
|
|
108 | (5) |
|
|
113 | (2) |
|
|
115 | (3) |
|
|
118 | (7) |
|
8 Prodromal Parkinson Disease |
|
|
125 | (12) |
|
|
125 | (2) |
|
Rem Sleep Behavior Disorder |
|
|
127 | (2) |
|
|
129 | (1) |
|
Rem Sleep Behavior Disorder Cohort Studies |
|
|
130 | (2) |
|
|
132 | (1) |
|
|
133 | (1) |
|
|
133 | (4) |
|
9 Clinical Features I: Initial Evaluation |
|
|
137 | (28) |
|
|
137 | (4) |
|
Nature of Diagnosis and Diagnostic Criteria |
|
|
141 | (3) |
|
|
144 | (3) |
|
|
147 | (3) |
|
|
150 | (9) |
|
|
159 | (1) |
|
|
160 | (5) |
|
10 Clinical Features II: Non-Motor Features |
|
|
165 | (28) |
|
|
165 | (2) |
|
|
167 | (6) |
|
Neuropsychiatry Disorders |
|
|
173 | (6) |
|
Sleep Disorders and Excessive Daytime Somnolence |
|
|
179 | (3) |
|
|
182 | (2) |
|
|
184 | (1) |
|
|
185 | (3) |
|
|
188 | (1) |
|
|
188 | (1) |
|
|
188 | (5) |
|
11 Clinical Features III: Natural History |
|
|
193 | (30) |
|
|
193 | (1) |
|
|
194 | (6) |
|
Pd Progression: Clinically Salient Features |
|
|
200 | (6) |
|
|
206 | (2) |
|
|
|
|
208 | (3) |
|
|
211 | (7) |
|
|
218 | (5) |
|
12 Pharmacology I: L-Dopa Pharmacokinetics and Pharmacodynamics |
|
|
223 | (14) |
|
|
223 | (1) |
|
Dopaminergic Neurotransmission |
|
|
224 | (2) |
|
|
226 | (2) |
|
|
228 | (4) |
|
|
232 | (1) |
|
Interactions of L-Dopa: Pharmacokinetics, Pharmacodynamics, and Disease Progression |
|
|
233 | (1) |
|
Conclusion and Future Directions |
|
|
234 | (3) |
|
13 Pharmacology II: Treating Parkinson Disease |
|
|
237 | (24) |
|
|
237 | (1) |
|
|
238 | (4) |
|
When the Honeymoon Is Over |
|
|
242 | (5) |
|
|
247 | (3) |
|
|
250 | (3) |
|
|
253 | (1) |
|
Other Symptomatic Therapies |
|
|
254 | (2) |
|
|
256 | (5) |
|
|
261 | (20) |
|
|
261 | (1) |
|
Deep Brain Stimulation: Rationale and Possible Mechanisms |
|
|
262 | (2) |
|
Deep Brain Stimulation: Indications |
|
|
264 | (3) |
|
Deep Brain Stimulation: Procedures |
|
|
267 | (1) |
|
Deep Brain Stimulation: Stn Dbs Benefits |
|
|
268 | (2) |
|
Deep Brain Stimulation: Gpi Dbs Benefits and Stn Versus Gpi Dbs |
|
|
270 | (1) |
|
Deep Brain Stimulation: Adverse Events |
|
|
271 | (1) |
|
|
272 | (1) |
|
Cell-Based and Gene Therapies |
|
|
272 | (2) |
|
|
274 | (3) |
|
|
277 | (1) |
|
|
277 | (1) |
|
|
277 | (1) |
|
|
278 | (1) |
|
Basic and Clinical Research Synergies |
|
|
279 | (2) |
Index |
|
281 | |